Bibliography
- Fernandez-Montero JV, Vispo E, Anta L, Rilpivirine - a next-generation non-nucleoside analogue for the treatment of HIV infection. Expert Opin Pharmacother 2012;13(7):1007-14
- Global HIV/AIDS response: epidemic update and health sector progress towards Universal Access. WHO/UNAIDS. UNICEF G S, 2011. Available from: http://www.who.int/hiv/pub/
- Kranzer K, Zeinecker J, Ginsberg P, Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PloS One 2010;5:e13801
- Braitstein P, Boulle A, Nash D, Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health 2008;17:47-55
- Cooper D, Moodley J, Zweigenthal V, Fertility intentions and reproductive health care needs of people living with HIV in Cape Town, South Africa: implications for integrating reproductive health and HIV care services. AIDS Behav 2009;13(Suppl 1):38-46
- World Health Organization. Global tuberculosis control 2009. Epidemiology s, fi nancing. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009. Available from: http://www.who.int/tb/, 2011. pgreihAF
- Boulle A, Van Cutsem G, Hilderbrand K, Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010;24:563-72
- Calmy AL, Ford N. Improving treatment outcome for children with HIV. Lancet 2011;377:1546-8
- Recommendations For a Public Health Approach. Antitetroviral Therapy for HIV Infection in Adolescents and Adults. World Health Organization G S; 2010
- Wasmuth JC, Rockstroh JK, Hardy WD. Drug safety evaluation of maraviroc for the treatment of HIV infection. Expert Opinion on Drug Safety 2012;11:161-74
- Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ 2004;82:935-9
- Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009;48:484-8
- Ford N, Lee J, Andrieux-Meyer I, Calmy A. Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV AIDS 2011;3:35-44
- Garvey L, Winston A. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs 2009;18:1035-41
- Hughes CA, Robinson L, Tseng A, MacArthur RD. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opin Pharmacother 2009;10:2445-66
- Fulco PP, McNicholl IR. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. Pharmacotherapy 2009;29:281-94
- Maltez F, Doroana M, Branco T, Valente C. Recent advances in antiretroviral treatment and prevention in HIV-infected patients. Curr Opin HIV AIDS 2011;6(Suppl 1):S21-30
- Rilpivirine (Edurant)–a new drug for HIV infection. Med Lett Drug Ther 2011;53:67-8
- Ghosh RK, Ghosh SM, Chawla S. Recent advances in antiretroviral drugs. Expert Opin Pharmacother 2011;12:31-46
- Eron JJ Jr. Antiretroviral therapy: new drugs, formulations, ideas, and strategies. Top HIV Med 2009;17:146-50
- Stellbrink HJ. Novel compounds for the treatment of HIV type-1 infection. Antivir Chem Chemother 2009;19:189-200
- Kiser JJ. Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV. Curr Opin HIV AIDS 2008;3:330-41